Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

A randomized, double-blin… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.

Artikel i vetenskaplig tidskrift
Författare Jan K Buitelaar
David Michelson
Marina Danckaerts
Christopher Gillberg
Thomas J Spencer
Alessandro Zuddas
Douglas E Faries
Shuyu Zhang
Joseph Biederman
Publicerad i Biological Psychiatry
Volym 61
Nummer/häfte 5
Sidor 694-699
ISSN 0006-3223
Publiceringsår 2007
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 694-699
Språk en
Länkar dx.doi.org/10.1016/j.biopsych.2006....
Ämnesord Adolescent, Adrenergic Uptake Inhibitors, Therapeutic use, Attention Deficit Disorder with Hyperactivity, Drug therapy, Child, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Propylamines, Therapeutic use, Recurrence, Prevention & control, Treatment Outcome
Ämneskategorier Psykiatri

Sammanfattning

BACKGROUND: The efficacy of atomoxetine in maintaining symptom response following 1 year of treatment was assessed in children and adolescents (n = 163) with DSM-IV defined attention-deficit/hyperactivity disorder (ADHD). METHODS: Subjects had previously responded to atomoxetine acutely and had completed 1 year of double-blind atomoxetine treatment. They were then randomly assigned in double-blind fashion to continued atomoxetine or placebo substitution for 6 months. RESULTS: Atomoxetine was superior to placebo in preventing relapse (Wilcoxon test, p = .008) and in maintaining symptom response (ADHD Rating Scale IV score, p < .001). Among subjects assigned to discontinuation, the magnitude of symptom return was generally to a level of severity less than that observed at study entry. CONCLUSIONS: Following 1 year of treatment with atomoxetine, continued treatment over the ensuing 6 months was associated with superior outcomes compared with placebo substitution. However, there was considerable variability between individuals in the magnitude of symptom return after drug discontinuation, suggesting that some subjects treated with atomoxetine for a year with good results may consolidate gains made during drug treatment and could benefit from a medication-free trial to assess the need for ongoing drug treatment.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?